Oncology biosimilars market to expand at an outstanding 27.5% CAGR between 2017 and 2025, for the market to become worth US$17,478.2 mn by the end of 2025 considerably up from its evaluated worth ofUS$2,100 mn in 2016.Oncology biosimilars are similar versions of oncology biologics that are manufactured by different companies and have been officially approved for cancer treatment

Source: Click here